AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Bank of Human Leukocytes From COVID-19 Convalescent Donors With an Anti-SARS-CoV-2 Cellular Immunity

RecruitingNAAges 18 Years - 70 YearsAllCentral Hospital, Nancy, France
💬

In plain words

What the trial is, and whether it could suit you

The SARS-CoV-2 identified in China in January 2020 is the cause of an unprecedented pandemic. The SARS-CoV-2 and each viral variant are responsible of a respiratory infectious disease, which can be asymptomatic. Nevertheless, a part of infected patients will experiment serious forms associated with a high mortality rate. Most serious forms present with lymphopenia and a functional exhaustion of speicifci T lymphocytes. Several studies showed that these quantitative and qualitative lymphocyte abnormalities are associated with unfavourable patients' outcome. The investigators hypothesized that the use of anti-viral T lymphocytes from convalescent COVID 19 donors could be helpful to improve the prognosis of COVID-19 serious forms. This study aims to demonstrate the feasibility of setting up a biobank that could allow the preservation and production of a cellular immunotherapy specific to SA

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patient hospitalised for proved SARS-CoV-2 infection in the infectious disease unit of the Nancy University Hospital who received a comprehensive information about the study, and accepted to participate * Patient who has an active cellular immunity against SARS-CoV-2 (biological definition: Elispot IFNgamma : \> 50 SFC/106 PBMC) Exclusion Criteria: * Patient hospitalised in Intensive car unit * Patient with haemoglobin \< 10 g/dl * Patient who take hypertension medication * Patient with cardiovascular history: Valvulopathy, conduction rythm disorders, arterial vascular insufficiency, congenital anomalies * Patient with auto-immune disease * Patient with medical history of solid or hematopoietic graft * Patient with active malignant disease (haematological or neoplasm) or considered in remission since less than 2 years * Patient with psychiatric disorders * Patient subject to a legal protection measure. * Patient with proved infectious disease * Asplenic patient * Pregnant or breastfeeding woman * Woman without contraception
💊

What it tests

  • Generation of a biobank allowing the cryopreservation of leucocytes from COVID19 convalescent donors
📍

Where

1 site
CHRU-Nancy - Hopitaux de Brabois - Batiment Philippe Canton
Vandœuvre-lès-Nancy, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy